Skip to the main content.

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals, "Cellicon Valley" and the "Golden Triangle

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals,

In this third instalment to our cell and gene blog series, author Dave Seaward explains where most ATMP technology is being delivered as well as providing insight into why.

Click here to gain an understanding of why investors believe significant returns will be made from these technologies.
The Future of Aseptic Manufacturing: Compact and Advanced Solutions

The Future of Aseptic Manufacturing: Compact and Advanced Solutions

David Johnson: 24 November 2025

As the pharmaceutical industry advances into more complex modalities, from biologics to cell and gene therapies, the need for flexible,...

Read More
Putting Annex 1 into Practice: What Small-Batch Manufacturers Need to Know

Putting Annex 1 into Practice: What Small-Batch Manufacturers Need to Know

David Johnson: 24 November 2025

In this webinar recap, David Johnson, Sales & Marketing Director at 3P innovation, and Tracy Moore, Principal Consultant at TM Pharma and former...

Read More
Advancing DPI blister filling: from the original invention to the latest technology.

Advancing DPI blister filling: from the original invention to the latest technology.

Carl Jones: 14 November 2025

Our DPI blister filling capabilities draw on long-standing experience, our founder, Tom Bailey, is one of the named inventors of the DPI filling...

Read More